ClinicalTrials.gg
CompletedNCT04548869Updated May 17, 2023

A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria

A Phase 1 interventional study of CDX-0159 in Cold Urticaria, Cold Contact Urticaria and Symptomatic Dermographism, sponsored by Celldex Therapeutics. Completed at 1 site in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-05-17.

Sponsored by Celldex Therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2022, 3 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
41
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a study to determine the safety of CDX-0159 in patients with Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria.

Read the detailed description

This study is an open label Phase 1 study evaluating the safety, pharmacokinetics, and pharmacodynamics of a single dose of CDX-0159 in patients with Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria who remain symptomatic despite treatment with antihistamines. Twenty patients with Cold Contact Urticaria, ten patients with Symptomatic Dermographism, and ten patients with Cholinergic Urticaria will be enrolled in four separate cohorts for a total of 40 patients.

Prospective patients will be screened with tests in clinic as well as daily at home diaries for 2 weeks prior to enrollment. CDX-0159 will be administered intravenously on Day 1. Post-treatment, patients will be followed for 12 weeks with an optional longer term follow up period.

02

Conditions studied

  • Cold Urticaria
  • Cold Contact Urticaria
  • Symptomatic Dermographism
  • Symptomatic Dermatographism
  • Cholinergic Urticaria
03

In context

Lead sponsor

Celldex Therapeutics is the lead sponsor of 45 studies on the registry; 3 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 1 (7%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Diagnosis of Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria which does not respond to antihistamines

    • Diagnosis for ≥ 3 months; symptoms of both hive (wheal) and itch/burning/painful sensation despite concurrent use of anti-histamines
    • During screening, in clinic, for Cold Contact Urticaria, patients must have a positive cold stimulation test, for Symptomatic Dermographism, patients must have a positive FricTest®, and for Cholinergic Urticaria, patients must have a positive pulse-controlled ergometry (PCE) provocation test
    • On stable dose of antihistamines
  2. Other than a diagnosis of Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria, no other conditions which would introduce additional risk factors or would interfere with the study procedures, as determined by the investigator, based on a medical evaluation
  3. Female and male patients must use highly effective from the time of the screening visit and for at least 150 days after receipt of study treatment
  4. Willing and able to comply with all study requirements and procedures including completion of a daily medication diary and questionnaires

Key Exclusion Criteria:

  1. A clearly defined diagnosis of hives or angioedema other than chronic urticaria.
  2. Receipt of prior biologic therapy (e.g.: omalizumab, dupilumab, ligelizumab) within past 3 months
  3. Treatment with immunosuppressives (e.g. systemic , cyclosporine, methotrexate, dapsone, cyclophosphamide, tacrolimus and mycophenolate mofetil, hydroxychloroquine or others) within 4 weeks or 5 half lives
  4. Active COVID-19 infection
  5. , or infection

There are additional criteria that your study doctor will review with you to confirm you are eligible for the study.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    CDX-0159

    20 patients with Cold Contact Urticaria, 10 patients with Symptomatic Dermographism, and 10 patients with Cholinergic Urticaria will be enrolled and treated with a single dose of CDX-0159

    Drug: CDX-0159

Interventions

06

What researchers measure

Primary outcomes

  1. Safety as assessed by the incidence and severity of adverse events

    Safety of a single dose of CDX-0159 as determined by adverse events

    Time frame: From Day 1 through week 12

Secondary outcomes

  1. For patients with Cold Contact Urticaria, Change in Critical Temperature Thresholds (CTT)

    The change from baseline in critical temperature thresholds over time as determined by provocation testing using the TempTest®

    Time frame: From Day 1 to Day 85

  2. For patients with Symptomatic Dermographism, change in provocation thresholds

    The change from baseline in provocation thresholds over time as determined by provocation testing using the FricTest®

    Time frame: From Day 1 to Day 85

  3. For patients with Cholinergic Urticaria, changes in baseline Urticaria Activity Score Provocation (UASprovo)

    Changes from baseline and percentage of responders as measured by UASprovo

    Time frame: From Day 1 to Day 85

  4. Changes from baseline in Urticaria Control Test (UCT)

    Changes from baseline and percentage of responders for the UCT and modified UCT

    Time frame: From Day 1 to Day 85

  5. Blood Biomarkers

    Pre-treatment and post-treatment blood samples will be collected and analyzed for changes in Stem Cell Factor

    Time frame: From Day 1 to Day 85

  6. Blood Biomarkers

    Pre-treatment and post-treatment blood samples will be collected and analyzed for changes in tryptase

    Time frame: From Day 1 to Day 85

  7. Pharmacokinetic Evaluation

    CDX-0159 concentrations will be measured.

    Time frame: From Day 1 to Day 85

  8. Immunogenicity Evaluation

    Patients will be monitored for the development of anti-drug antibodies.

    Time frame: From Day 1 to Day 85

07

Study locations

1 site
  • Charite University
    Berlin, 10117, Germany
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in Dec 2022, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2020
First posted
Sep 16, 2020
StartActual
Nov 24, 2020
Primary completionActual
Dec 16, 2022
CompletionActual
May 12, 2023
Last update
May 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04548869
Responsible party
Sponsor
First posted
Sep 16, 2020
Start date
Nov 24, 2020
Primary completion
Dec 16, 2022
Completion
May 12, 2023
Last update
May 17, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Barzolvolimab

Start the discussion